Articles from Perspectum

Perspectum and InHealth have announced a new national diagnostics partnership that will significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre (CDC). The Oxford CDC, one of NHS England’s leading sites, served more than 60,000 patients this year, a figure expected to climb to over 100,000 by 2027 through extended operating hours, additional facilities and expanded pathways delivered by InHealth.

Newly published economic modeling concludes that Perspectum’s proprietary biomarker cT1 may help US Veterans Administration (VA) health care enrollees gain better access and treatment for MASH (metabolic dysfunction-associated steatohepatitis), an advanced stage of MASLD (metabolic dysfunction-associated steatotic liver disease).

Nature Medicine today published a study showing that Perspectum’s iron corrected T1, or cT1, predicts liver-related and cardiac outcomes, including morbidity. Liver disease is a modifiable cardiac risk factor, and this study confirmed that it can be quantified with MRI cT1.

Perspectum today released the results of a multinational study showing that LiverMultiScan can reduce liver biopsies, lead to fewer specialist consultations, and improve the rate of diagnosis for patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The groundbreaking study was published in Nature Communications Medicine and shows that MRI for patients with MASLD is cost-effective in Europe.

Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool (DDT) Research Grant to evaluate a novel biomarker aimed at addressing the unmet needs of patients with rare diseases. This award highlights Perspectum’s steadfast commitment to supporting targeted therapies that improve patient care and quality of life.

Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated steatohepatitis (MASH). This research affirms the utility of quantitative MRI imaging as an alternative to liver biopsy in some clinical trials and in patient care management.

Liver disease, the UK’s third leading cause of premature death, poses a significantly greater threat to human health than previously recognized.

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the second close of its $55 million Series C funding round. The additional $19 million investment was led by Oppenheimer. The second close of the Series C funding brings the total amount raised since inception to circa $140 million.

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round. The new $36 million investment was led by Oppenheimer Holdings. The Series C funding brings the total amount raised since inception to circa $120 million.

Perspectum and Nuance Communications, Inc., a Microsoft company, announced today at the 108th Radiological Society of North America’s (RSNA) Annual Meeting (RSNA Booth #7938) their collaboration to deliver at scale Perspectum’s integrated digital platform suite for metabolic disease care and management. This new collaboration will help accelerate adoption of Perspectum’s non-invasive quantitative multiparametric MR (Magnetic Resonance) software services across the over 12,000 US health care facilities using Nuance’s expanding Precision Imaging Network™.

A health economic study performed by NHS England’s Oxford Academic Health Science Network (AHSN) showed that Perspectum’s LiverMultiScan – an artificial intelligence-enhanced, noninvasive liver health diagnostic tool – is a cost-effective alternative to painful, invasive liver biopsies for monitoring disease activity and treatment response in patients with autoimmune hepatitis (AIH).

The American Medical Association (AMA) has issued two unique Category III Current Procedural Terminology (CPT®) codes for Quantitative Magnetic Resonance Cholangiopancreatography (QMRCP), CPT 0723T and CPT +0724T, otherwise known in the market as MRCP+, which can help clinicians assess patients with diseases of the biliary tree and pancreatic duct. Effective July 1, 2022, the Centers for Medicare & Medicaid Services (CMS) has issued appropriate reimbursement for the MRCP+ procedure.

A first-of-its-kind study published in eClinicalMedicine - The Lancet, found that LiverMultiScan-cT1 (an MRI-derived non-invasive tissue biomarker), improved autoimmune hepatitis (AIH) management by identifying patients in biochemical remission as well as patients in deep remission, with undetected, active sub-clinical disease at a high risk of disease relapse.

AIM Specialty Health deems LiverMultiScan® medically necessary for evaluating diffuse liver diseases, covering over 77 million US lives. This new AIM Advanced Imaging guideline includes the stand-alone CPT Code 0648T used when billing for the LiverMultiScan procedure.

Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children.” This 10-year collaborative study includes 12 geographically-diverse children’s hospitals in the United States and one Canadian children’s hospital.

Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services.

Perspectum®’s LiverMultiScan® significantly enhanced patient understanding of chronic liver disease (CLD) care in a first-of-its-kind study published in the Journal of Patient-Reported Outcomes, highlighting how it can help improve adherence to lifestyle interventions. Using a qualitative, interview-based approach, patients with CLD reported their first-hand experiences and perceptions of how LiverMultiScan’s easy-to-understand information can educate and empower them towards self-management of their disease condition.

Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing (Precision1, NCT04597710) is underway. Participants with primary or secondary liver cancer will be recruited from Hampshire Hospitals NHS Foundation Trust in Basingstoke. Perspectum will also partner with experts in clinical applications of genomic sequencing in patients with cancer from the University of Oxford.

Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians to more accurately diagnose and monitor patients with chronic metabolic diseases, announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.

Perspectum announced that it has signed a strategic business partnership with Marubeni Corporation (“Marubeni”) to support entry of Perspectum’s AI diagnostic technology, called LiverMultiScan, into the Japanese market.

New research published in BMJ Open outlines findings from a study on multiorgan impairment in individuals with persistent symptoms following recovery from COVID-19 infection— a condition referred to as long COVID. The study included characterization of organ function using global medical technology company Perspectum’s non-invasive imaging technology.

Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians to more accurately diagnose and monitor patients with chronic metabolic diseases, multi-organ pathologies and cancer, announced the appointment of Annalisa Jenkins, MBBS, FRCP to its Board of Directors.